Dr. Anderson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-4673Fax+1 214-645-2661- Is this information wrong?
Summary
- Dr. Larry Anderson is a hematologist in Dallas, TX and is affiliated with University of Texas Southwestern Medical Center and William P. Clements, Jr. University Hospital. He received his MD from University of Texas Medical School Houston, PhD from MD Anderson Cancer Center/GSBS, internal medicine residency at Mayo Clinic Rochester, and Oncology fellowship at Fred Hutchinson Cancer Research Center/University of Washington. He has been in practice 14 years. He specializes in plasma cell disorders and is experienced in bone marrow transplantation, multiple myeloma, amyloidosis, and waldenstrom's macroglobulinemia.
Education & Training
- University of WashingtonFellowship, Hematology and Medical Oncology, 2003 - 2006
- University of Washington School of MedicineFellowship, Oncology/Bmt, 2003 - 2006
- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2000 - 2003
- McGovern Medical School at UTHealthClass of 2000
Certifications & Licensure
- TX State Medical License 2008 - 2025
- WA State Medical License 2003 - 2010
- MN State Medical License 2001 - 2003
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Best Doctors D Magazine, 2021-2023
- Texas Super Doctors Texas Monthly Magazine, 2018-2023
- Man of the Year Leukemia & Lymphoma Society North Texas, 2015
- Join now to see all
Clinical Trials
- Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
- Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
- Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsRacial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy.Lauren C Peres, Laura B Oswald, Christen M Dillard, Gabriel De Avila, Taiga Nishihori, Brandon J Blue, Ciara L Freeman, Frederick L Locke, Melissa Alsina, Omar Castane...> ;Blood Advances. 2024 Jan 9
- Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hi...> ;Journal of the National Comprehensive Cancer Network : JNCCN.
- Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengas...> ;Journal of the National Comprehensive Cancer Network : JNCCN.
- Join now to see all
Journal Articles
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaNikhil C Munshi, Larry D Anderson, Deepu Madduri, Sagar Lonial, Noopur Raje, Fabio Petrocca, Kristen Hege, The New England Journal of Medicine
Abstracts/Posters
- Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...Larry D. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 ...Larry D. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based TherapyLarry D. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
- Researchers Uncover Mutated Genes Involved in Lung Cancer; One Affects NonsmokersOctober 24th, 2017
- International Women’s Day: Perspectives in Medicine, Nursing, and Fellowship from Richa Thakur, Nida Khan, Lauren Ghazal, and Gurbakhash KaurMarch 9th, 2024
- A Pioneer in Plasma Cell DisordersMarch 7th, 2021
- Join now to see all
Professional Memberships
- Member
- Member
- Member
- AstctMember
Hospital Affiliations
- University of Texas Southwestern Medical CenterDallas, Texas
- William P. Clements, Jr. University HospitalDallas, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: